Bright Minds Biosciences DRUG 深 沪
等待开盘 10-07 09:30:00 美东时间
48.25
-1.540
-3.09%
华盛通- 最 高50.00
- 今 开49.79
- 成交量 10.77万股
- 最 低 47.60
- 昨 收 49.79
- 总市值 4.73亿
- 52周最高 123.75
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 47.60
- 委 比 32.89%
- 总股本 981.21万
- 历史最高 123.75
- 量 比 0.97
- 振 幅 4.82%
- 历史最低 0.93
- 每 手 1
- 风险率 11.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Bright Minds Biosciences will participate in the FPWR 2026 Research Symposium and PWS Family Conference to discuss its clinical program targeting Prader-Willi Syndrome (PWS). The company is developing BMB-101, a selective 5-HT2C agonist, to address both hyperphagia and neurobehavioral symptoms of PWS. The NOVA Phase 2a study is evaluating BMB-101's efficacy and safety over 16 weeks. Bright Minds has expanded its Scientific Advisory Board with glo...
09-30 21:30
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
08-18 00:24
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Vistagen appoints Douglas J. Williamson, MD, to its Board of Directors. With nearly 30 years of leadership experience in neuroscience drug development, clinical research, and regulatory strategy, Dr. Williamson will provide valuable insights as Vistagen advances its pipeline and evaluates growth opportunities. He previously served as Chief Medical Officer at QurAlis Corporation and held senior roles at Acadia Pharmaceuticals, Avadel Pharmaceutica...
07-31 12:30
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220
Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.
05-21 01:28
